<DOC>
	<DOC>NCT00558064</DOC>
	<brief_summary>To demonstrate that a fixed-dose combination of telmisartan 40 mg plus amlodipine 5 mg is superior to amlodipine 5 mg alone in patients with essential hypertension and inadequately controlled with amlodipine 5 mg monotherapy.</brief_summary>
	<brief_title>Filtered Trial for Amlodipine Non-responder</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1. Essential hypertensive patients satisfying all of the following criteria; 2. Male or Female 3. Age &gt; 20 years 4. Outpatient 5. Patients who are able to stop current antihypertensive therapy at Visit 1 if taking any antihypertensive medications 6. Patients with an ability to provide written informed consent in accordance with the related laws and guidelines such as Good Clinical Practice (GCP) and the Pharmaceutical Affairs Law. 1. Taking four or more antihypertensive medications 2. Secondary hypertension 3. Mean seated diastolic blood pressure (DBP) &gt; 114 mmHg and/or mean seated systolic blood pressure (SBP) &gt; 200 mmHg at Visit 1, 2, 3, or 4, or mean seated DBP &lt; 90 mmHg at Visit 3. 4. Sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias 5. Congestive heart failure patients with the New York Heart Association (NYHA) functional class IIIIV 6. History of myocardial infarction or cardiac surgery within last 6 months 7. History of coronary artery bypass graft or percutaneous coronary intervention (PCI) within last 3 months 8. History of unstable angina within last 3 months 9. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve 10. History of stroke or transient ischemic attack within last 6 months 11. History of sudden exacerbation of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors, or patients with postrenal transplant or postnephrectomy 12. Experienced characteristic symptoms of angioedema during treatment with ARBs or ACE inhibitors 13. Known hypersensitivity to any component of the investigational drug , or a known hypersensitivity to dihydropyridine derived drugs 14. Hepatic and/or renal dysfunction 15. Diagnosed biliary atresia or cholestasis 16. Hyperkalemia 17. Dehydration 18. Sodium deficiency 19. Chronic administration of high doses of acidic nonsteroidal antiinflammatory drugs (NSAIDs) 20. Patients who cannot change to the restricted administration and dosage during study period 21. Premenopausal women who meet any one of the following 1 3: Pregnant or possibly pregnant (1) Nursing (2) Desire to become pregnant during study period (3) 22. Drug or alcohol dependency 23. Complication of malignant tumour or a disease requiring immunosuppressants 24. Compliance of &lt; 80% or &gt; 120% during the runin period 25. Receiving any investigational therapy within 3 months 26. Judged to be inappropriate by the investigator or the subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>